|
|
|
|
|
Dasatinib Monohydrate |
|
N -(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)- 1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazole carboxamide monohydrate |
|
[863127-77-9] |
|
Dasatinib (BMS-354825) is a novel, oral, potent, multi-targeted kinase inhibitor of Bcr-Abl and Src family kinases (SFK) and is a promising cancer therapeutic agent. Preclinical data indicate that dasatinib is 325-fold more potent than imatinib against cells expressing wild-type Bcr-Abl, and that dasatinib is active against 18 of 19 Bcr-Abl mutations known to cause imatinib resistance |
|
Description:Off-white to pale yellow power .
Solubility: Insoluble in water, slightly soluble in methanol and ethanol.
Related substances:Any single impurities: NMT0.5% Total impurities: NMT1.0%
Assay(HPLC):min 99%
|
Industrial field |
pharmaceutical |
|
|
|
|
|
|
|
There are no existing companies to distribute selected chemical product |
|
|
|
|
|